{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:47:23Z","timestamp":1782298043611,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chemotherapy-induced nausea and vomiting substantially impair patients\u2019 quality of life despite considerable advances in supportive care. Neurokinin-1 receptor antagonists, including oral aprepitant and intravenous fosaprepitant, constitute essential components of antiemetic regimens for highly emetogenic chemotherapy. In this prospective, non-randomized observational study, we compared the efficacy of oral aprepitant and intravenous fosaprepitant administered in combination with 5-hydroxytryptamine-3 receptor antagonists and dexamethasone in 136 chemotherapy-naive patients receiving cisplatin- or doxorubicin\u2013cyclophosphamide-based regimens. Complete response rates during the acute (0\u201324 h), delayed (24\u2013120 h), and overall (0\u2013120 h) phases were comparable between the two groups, with no statistically significant differences in emesis severity. Multivariable analyses further demonstrated similar effectiveness irrespective of age, sex, or chemotherapy regimen. These findings indicate that no statistically significant differences in antiemetic efficacy were observed between aprepitant and fosaprepitant in routine clinical practice. Fosaprepitant may therefore represent a practical alternative when oral administration is not feasible.<\/jats:p>","DOI":"10.3390\/curroncol33070381","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:57:24Z","timestamp":1782287844000},"page":"381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy\u2014A Real-World Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-0277","authenticated-orcid":false,"given":"Beyza","family":"\u00dcnl\u00fc","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena Ece","family":"Davarc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-7552","authenticated-orcid":false,"given":"Ya\u015far","family":"Culha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sivas Numune Hospital, Sivas 58060, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6376-8399","authenticated-orcid":false,"given":"Duygu","family":"\u00d6za\u015fk\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariz Emrah","family":"\u00d6zkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-8934","authenticated-orcid":false,"given":"Sedat","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Baykara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","first-page":"497","article-title":"Chemotherapy-induced nausea and vomiting\u2014Incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2006","journal-title":"Support. Care Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003495-200969050-00002","article-title":"Pharmacological management of chemotherapy-induced nausea and vomiting: Focus on recent developments","volume":"69","author":"Navari","year":"2009","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","article-title":"Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control","volume":"8","author":"Schnell","year":"2003","journal-title":"Oncologist"},{"key":"ref_5","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: Optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am. Health Drug Benefits"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003495-200060030-00002","article-title":"Potential of Substance P Antagonists as Antiemetics","volume":"60","author":"Diemunsch","year":"2000","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2165\/11203680-000000000-00000","article-title":"Aprepitant: A review of its use in the prevention of nausea and vomiting","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1586\/14737140.8.11.1733","article-title":"Fosaprepitant: A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting","volume":"8","author":"Navari","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.17219\/acem\/157061","article-title":"The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review","volume":"32","author":"Liu","year":"2023","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70171","DOI":"10.1002\/1545-5017.70171","article-title":"Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator-Initiated Randomized, Open-Label, Non-Inferiority Trial","volume":"73","author":"Rasheed","year":"2026","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Do\u011fan, A., Er\u00f6lmez, H.N., Akda\u011f, G., Y\u0131ld\u0131r\u0131m, S., and Sever, \u00d6.N. (2026). Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33020078"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin\u2014The Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0959-8049(00)00416-0","article-title":"Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis","volume":"37","author":"Cocquyt","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/cncr.10516","article-title":"Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869","volume":"94","author":"Lichinitser","year":"2002","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0091270007301800","article-title":"Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects","volume":"47","author":"Lasseter","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","article-title":"Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Cisplatin Therapy: Randomized, Double-Blind Study Protocol\u2014EASE","volume":"29","author":"Grunberg","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncologist"},{"key":"ref_20","first-page":"1171","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2009","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejca.2005.01.024","article-title":"The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials","volume":"41","author":"Warr","year":"2005","journal-title":"Eur. J. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:01:17Z","timestamp":1782295277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070381"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070381","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}